Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 21 studies | 38% ± 16% | |
monocyte | 15 studies | 30% ± 11% | |
non-classical monocyte | 11 studies | 27% ± 8% | |
microglial cell | 11 studies | 37% ± 15% | |
macrophage | 11 studies | 25% ± 12% | |
myeloid cell | 9 studies | 34% ± 12% | |
dendritic cell | 7 studies | 30% ± 11% | |
plasmacytoid dendritic cell | 7 studies | 23% ± 8% | |
conventional dendritic cell | 6 studies | 32% ± 21% | |
neutrophil | 5 studies | 27% ± 6% | |
mononuclear phagocyte | 4 studies | 21% ± 1% | |
endothelial cell | 3 studies | 21% ± 5% | |
lymphocyte | 3 studies | 18% ± 1% | |
epithelial cell | 3 studies | 19% ± 2% | |
CD4-positive, alpha-beta T cell | 3 studies | 21% ± 6% | |
intermediate monocyte | 3 studies | 42% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 3187.27 | 1809 / 1809 | 100% | 15.93 | 471 / 472 |
breast | 100% | 3206.53 | 459 / 459 | 100% | 15.23 | 1115 / 1118 |
thymus | 100% | 2024.73 | 652 / 653 | 100% | 14.56 | 603 / 605 |
esophagus | 99% | 1813.88 | 1437 / 1445 | 100% | 17.44 | 183 / 183 |
stomach | 99% | 1911.55 | 357 / 359 | 100% | 14.36 | 286 / 286 |
prostate | 100% | 2339.36 | 244 / 245 | 100% | 13.80 | 501 / 502 |
intestine | 99% | 1983.18 | 961 / 966 | 100% | 12.53 | 525 / 527 |
lung | 100% | 4627.76 | 577 / 578 | 99% | 16.05 | 1146 / 1155 |
bladder | 100% | 1877.48 | 21 / 21 | 99% | 12.47 | 499 / 504 |
uterus | 100% | 2194.29 | 170 / 170 | 98% | 13.02 | 452 / 459 |
kidney | 99% | 1454.02 | 88 / 89 | 99% | 13.64 | 889 / 901 |
ovary | 99% | 1920.26 | 179 / 180 | 98% | 11.96 | 421 / 430 |
pancreas | 97% | 1300.99 | 318 / 328 | 99% | 13.86 | 176 / 178 |
brain | 96% | 1658.41 | 2544 / 2642 | 99% | 14.52 | 701 / 705 |
liver | 100% | 1332.82 | 226 / 226 | 95% | 7.89 | 385 / 406 |
adrenal gland | 100% | 2385.58 | 258 / 258 | 83% | 6.05 | 191 / 230 |
adipose | 100% | 3872.42 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 10.19 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 21.99 | 29 / 29 |
peripheral blood | 100% | 18904.47 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 7241.17 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.88 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.43 | 1 / 1 |
blood vessel | 99% | 2117.79 | 1320 / 1335 | 0% | 0 | 0 / 0 |
heart | 95% | 1279.18 | 815 / 861 | 0% | 0 | 0 / 0 |
muscle | 31% | 230.35 | 249 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050832 | Biological process | defense response to fungus |
GO_0072537 | Biological process | fibroblast activation |
GO_0006954 | Biological process | inflammatory response |
GO_2000340 | Biological process | positive regulation of chemokine (C-X-C motif) ligand 1 production |
GO_0038173 | Biological process | interleukin-17A-mediated signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0032747 | Biological process | positive regulation of interleukin-23 production |
GO_0009615 | Biological process | response to virus |
GO_0032736 | Biological process | positive regulation of interleukin-13 production |
GO_1900017 | Biological process | positive regulation of cytokine production involved in inflammatory response |
GO_0032754 | Biological process | positive regulation of interleukin-5 production |
GO_0030163 | Biological process | protein catabolic process |
GO_0071621 | Biological process | granulocyte chemotaxis |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0072538 | Biological process | T-helper 17 type immune response |
GO_0032755 | Biological process | positive regulation of interleukin-6 production |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0097400 | Biological process | interleukin-17-mediated signaling pathway |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0030368 | Molecular function | interleukin-17 receptor activity |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IL17RA |
Protein name | Interleukin 17 receptor A Interleukin-17 receptor A (IL-17 receptor A) (IL-17RA) (CDw217) (CD antigen CD217) |
Synonyms | IL17R |
Description | FUNCTION: Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A . Receptor for IL17F . Binds to IL17A with higher affinity than to IL17F . Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC . Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC . Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation . Involved in antimicrobial host defense primarily promoting neutrophil activation and recruitment at infection sites to destroy extracellular bacteria and fungi (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Plays a role in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms. Enhances immunity against West Nile virus by promoting T cell cytotoxicity. Contributes to Influenza virus clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity). Receptor for IL17C as part of a heterodimeric complex with IL17RE . .; FUNCTION: (Microbial infection) Receptor for SARS coronavirus-2/SARS-CoV-2 virus protein ORF8, leading to IL17 pathway activation and an increased secretion of pro-inflammatory factors through activating NF-kappa-B signaling pathway. . |
Accessions | ENST00000694950.1 A0A8Q3WKC6 Q96F46 A0A8Q3WK71 ENST00000477874.1 ENST00000612619.2 [Q96F46-2] ENST00000319363.11 [Q96F46-1] |